Answers are grounded in this paper and cite their sources.
Long-term cohort study finds dupilumab reduces medication use in CRSwNP, highlighting improved disease management.
In this real-world cohort, Dupilumab treatment led to a sustained overall reduction in concomitant medication use, thereby lowering pharmacological burden while improving disease control.
No takes yet. Share an insight, caveat, or question.
Berbalk et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: